A year after raising $66m in a series B, the Zug, Switzerland-headquartered start-up biotech, Pharvaris B.V. has just raised a hefty $80m in a series C round, with its lead product expected to enter Phase II clinical trials in 2021.
Pharvaris Oral HAE Candidate Heading Into Phase II In 2021
$80m Series C Completed
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.
